This article is more than 5 years old. Information may no longer be current.

Boehringer Ingelheim receives method of treatment patent for epinastine

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — The U.S. Patent and Trademark Office has issued a method of treatment patent related to epinastine ophthalmic solution for allergic conjunctivitis, according to a press release from Inspire Pharmaceuticals.

The patent, titled "Treating conjunctivitis by administering an epinastine solution to the conjunctiva," was issued to Boehringer Ingelheim International, the developer of the invention, and will expire in November 2020.

Licensed from Boehringer and originally developed by Allergan for relieving itching associated with ocular allergies, Elestat (epinastine HCl ophthalmic solution 0.05%) is a topical antihistamine with mast cell stabilizing and anti-inflammatory activity, according to the release.

After the drug's approval in 2003, Inspire entered into a co-promotion agreement with Allergan under which Inspire obtained primary rights to sell, promote and market the drug in the United States.